Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD‐L1 in Breast Cancer: A Focus on Epithelial‐Mesenchymal Transition …
M Segovia-Mendoza, S Romero-Garcia… - Journal of …, 2021 - Wiley Online Library
Breast cancer is the most common neoplasm diagnosed in women around the world.
Checkpoint inhibitors, targeting the programmed death receptor‐1 or ligand‐1 (PD‐1/PD …
Checkpoint inhibitors, targeting the programmed death receptor‐1 or ligand‐1 (PD‐1/PD …
Elucidating the Influence of MPT-driven necrosis-linked LncRNAs on immunotherapy outcomes, sensitivity to chemotherapy, and mechanisms of cell death in clear …
J Huang, M Liu, H Chen, J Zhang, X Xie, L Jiang… - Frontiers in …, 2023 - frontiersin.org
Background Clear cell renal carcinoma (ccRCC) stands as the prevailing subtype among
kidney cancers, making it one of the most prevalent malignancies characterized by …
kidney cancers, making it one of the most prevalent malignancies characterized by …
Ultrasound targeting of microbubble-bound anti PD-L1 mAb to enhance anti-tumor effect of cisplatin in cervical cancer xenografts treatment
Y Ma, J Han, J Jiang, Z Zheng, Y Tan, C Liu, Y Zhao - Life Sciences, 2020 - Elsevier
Abstract Aims Anti-PD-L1 monoclonal antibody (mAb)-conjugated ultrasound (US) lipid-
shelled microbubbles (PD-L1-MBs) were successfully synthesized to investigate whether …
shelled microbubbles (PD-L1-MBs) were successfully synthesized to investigate whether …
[引用][C] Research progress and clinical application of PD-1/PD-L1 in acute myeloid leukemia
S Yingqing, L Zhuogang, W Hongtao